PSMA-directed endoRadiothErapy of Castration-reSISTant Prostate Cancer (RESIST-PC). A Phase II Clinical Trial
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2018
At a glance
- Drugs PSMA 617 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms PERCIST; RESIST-PC
- 25 Sep 2018 Planned primary completion date changed from 12 Jul 2018 to 31 Dec 2018.
- 25 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated